From vaccines to AI-powered healthcare, America's medical breakthroughs over 250 years have transformed disease prevention, ...

Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

Moderna ( MRNA +10.01%) stock jumped about 10% on Thursday to $79.76 -- a fresh high for the year and the latest leg of a run ...

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...

The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...

To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.

From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?

A recent survey suggests that using apps and artificial intelligence for health advice may be linked to vaccine distrust.

Moderna shares climbed 13% to reach $67.50 on June 26, tracking toward the strongest close since September 2024 The biotech firm unveiled mRNA-6007, its inaugural in vivo CAR-T initiative, focused on ...

The study also reviews the great potential of mRNA vaccines to treat influenza, RSV, cancer, and autoimmune diseases.